Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;13(1):e1499.
doi: 10.1002/wsbm.1499. Epub 2020 Jul 26.

Liver fibrosis: Pathophysiology and clinical implications

Jennifer Berumen  1 , Jacopo Baglieri  1   2 , Tatiana Kisseleva  1 , Kristin Mekeel  1
Affiliations
Review

Liver fibrosis: Pathophysiology and clinical implications

Jennifer Berumen et al. WIREs Mech Dis. 2021 Jan.

Abstract

Liver fibrosis is a clinically significant finding that has major impacts on patient morbidity and mortality. The mechanism of fibrosis involves many different cellular pathways, but the major cell type involved appears to be hepatic stellate cells. Many liver diseases, including Hepatitis B, C, and fatty liver disease cause ongoing hepatocellular damage leading to liver fibrosis. No matter the cause of liver disease, liver-related mortality increases exponentially with increasing fibrosis. The progression to cirrhosis brings more dramatic mortality and higher incidence of hepatocellular carcinoma. Fibrosis can also affect outcomes following liver transplantation in adult and pediatric patients and require retransplantation. Drugs exist to treat Hepatitis B and C that reverse fibrosis in patients with those viral diseases, but there are currently no therapies to directly treat liver fibrosis. Several mouse models of chronic liver diseases have been successfully reversed using novel drug targets with current therapies focusing mostly on prevention of myofibroblast activation. Further research in these areas could lead to development of drugs to treat fibrosis, which will have invaluable impact on patient survival. This article is categorized under: Metabolic Diseases > Molecular and Cellular Physiology.

Keywords: chirrosis; clinical stages of liver fibrosis; hepatic stellate cells; hepatocellular carcinoma; liver fibrosis.

PubMed Disclaimer

Figures

Figure. 1
Figure. 1. Pathophysiology of liver fibrosis.
See this image and copyright information in PMC

References

    1. Alkhouri N, Lawitz E, & Noureddin M (2019). Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment. Hepatol Commun, 3(5), 605–613. doi:10.1002/hep4.1342 - DOI - PMC - PubMed
    1. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, . . . Bendtsen F (2015). Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 149(2), 389–397 e310. doi:10.1053/j.gastro.2015.04.043 - DOI - PMC - PubMed
    1. Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, . . . Brenner DA (2012). Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology, 56(6), 2316–2327. doi:10.1002/hep.25938 - DOI - PMC - PubMed
    1. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, . . . Isner JM (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J, 18(14), 3964–3972. doi:10.1093/emboj/18.14.3964 - DOI - PMC - PubMed
    1. Baas M, Gouw ASH, van den Heuvel MC, Hepkema BG, Peeters P, Verkade H, & Scheenstra R (2017). Unique clinical conditions associated with different acinar regions of fibrosis in long-term surviving pediatric liver grafts. Pediatr Transplant, 21(7). doi:10.1111/petr.12988 - DOI - PubMed

Publication types